Evidence map›Paper›PMID 27215453›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2016

[Clinical Analysis of 107 NSCLC Patients Harboring KRAS Mutation].

Quan Zhang, Jinghui Wang, Xi Li, Hui Zhang, Jingying Nong, Na Qin, Xinyong Zhang, Yuhua Wu, Xinjie Yang, Jalin Lv and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Prognostic value ofOncology letters · 2019
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Quan ZhangDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, 
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Jinghui WangDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, 
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Xi LiDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, 
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Hui ZhangDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, 
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Jingying NongDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, 
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Na QinDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, 
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Xinyong ZhangDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, 
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Yuhua WuDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, 
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Xinjie YangDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, 
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Jalin LvDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, 
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Shucai ZhangDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, 
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Beijing Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKirsten rat sarcoma viral oncogene (KRAS) mutation is one of the major driver genes of non-small cell lung cancer (NSCLC). KRAS is a resistant predictor of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which raises controversy because of its role in chemotherapy sensitivity and prognosis. The aim of this study is to accumulate clinical experience in treating NSCLC patients harboring KRAS mutation.

methodsA total of 107 NSCLC patients harboring KRAS mutation were analyzed retrospectively. The efficacy was analyzed in terms of first-line chemotherapy or EGFR-TKIs therapy.

resultsThe objective response rate (ORR) to first-line chemotherapy of 52 patients with advanced disease harboring KRAS mutation was 9.6%. The disease control rate (DCR) was 53.8%, and the median progression-free survival (PFS) was 3 months. The ORR to EGFR-TKIs therapy in 21 patients harboring KRAS mutation and EGFR/KRAS co-mutation was 9.5%; the DCR was 23.8%, and the median PFS was 1 month. The ORR and DCR to EGFR-TKIs therapy of patients with EGFR/KRAS co-mutation were significantly higher than those of patients with KRAS mutation (50% vs 0, P=0.029; 75% vs 11.8%, P=0.043); the median PFS was also significantly longer (3 months vs 1 month, P=0.004).

conclusionsThe efficacy to first-line chemotherapy and EGFR-TKIs therapy in NSCLC patients harboring KRAS mutation was poor; thus, new drugs should be developed. Furthermore, the existence of EGFR/KRAS co-mutation was confirmed. Hence, EGFR-TKIs therapy should be administered to patients with EGFR/KRAS co-mutation.

Indexed as

MutationAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungErbB ReceptorsFemaleHumansLung NeoplasmsMaleMiddle AgedProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)Retrospective StudiesYoung AdultErbB ReceptorsKRAS protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)

Identifiers

PMID27215453
PMCPMC5973060
OpenAlexW2399272182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.